Table 1 Selected patient and tumor characteristics
Gefitinib N = 28 | Erlotinib N = 31 | ||||
|---|---|---|---|---|---|
Age (at diagnosis) | Median (range) | 63.5 (37–80) | 65.8 (34–79) | ||
N | % | N | % | ||
Gender | Male | 20 | 71 | 20 | 65 |
Female | 8 | 29 | 11 | 35 | |
Smoker | No | 7 | 25 | 12 | 39 |
Yes | 20 | 71 | 16 | 52 | |
Unknown | 1 | 4 | 3 | 10 | |
Histology | Squamous cell Ca | 4 | 14 | 3 | 10 |
Adenocarcinoma | 18 | 64 | 22 | 71 | |
Large cell Ca | 1 | 4 | - | - | |
Mixed type Ca | 1 | 4 | 1 | 3 | |
Undifferentiated/Unclassified Ca | 3 | 11 | 2 | 6 | |
Unknown | 1 | 4 | 3 | 10 | |
Grade | 1 | 3 | 11 | 2 | 6 |
2 | 4 | 14 | 7 | 23 | |
3 | 6 | 21 | 6 | 19 | |
Undifferentiated | 3 | 11 | - | - | |
Unknown | 12 | 43 | 16 | 52 | |
Performance status | 0 | 6 | 21 | 7 | 23 |
1 | 15 | 54 | 16 | 52 | |
2 | - | - | 1 | 3 | |
Unknown | 7 | 25 | 7 | 23 | |
Line of TKI treatment | 1st | 4 | 14 | 9 | 29 |
2nd | 18 | 64 | 15 | 48 | |
>2nd | 6 | 21 | 7 | 22 | |